JP2022512658A - Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる - Google Patents

Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる Download PDF

Info

Publication number
JP2022512658A
JP2022512658A JP2021519735A JP2021519735A JP2022512658A JP 2022512658 A JP2022512658 A JP 2022512658A JP 2021519735 A JP2021519735 A JP 2021519735A JP 2021519735 A JP2021519735 A JP 2021519735A JP 2022512658 A JP2022512658 A JP 2022512658A
Authority
JP
Japan
Prior art keywords
disease
platelets
syndrome
cells
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512658A5 (enExample
Inventor
グ，ヂェン
ワン，ジンチャン
チャン，シュードン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2022512658A publication Critical patent/JP2022512658A/ja
Publication of JP2022512658A5 publication Critical patent/JP2022512658A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
JP2021519735A 2018-10-10 2019-10-10 Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる Pending JP2022512658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743857P 2018-10-10 2018-10-10
US62/743,857 2018-10-10
PCT/US2019/055524 WO2020077037A1 (en) 2018-10-10 2019-10-10 Pd-l1 presenting platelets reverse new-onset type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2022512658A true JP2022512658A (ja) 2022-02-07
JP2022512658A5 JP2022512658A5 (enExample) 2024-02-22

Family

ID=70165144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519735A Pending JP2022512658A (ja) 2018-10-10 2019-10-10 Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる

Country Status (6)

Country Link
US (1) US20210353679A1 (enExample)
EP (1) EP3863650A4 (enExample)
JP (1) JP2022512658A (enExample)
CN (1) CN113164523A (enExample)
CA (1) CA3115778A1 (enExample)
WO (1) WO2020077037A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694204A (zh) * 2021-08-26 2021-11-26 南方医科大学南方医院 一种治疗骨髓炎的组合物及其应用
CN114984219B (zh) * 2022-03-29 2023-06-27 浙江大学 Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途
CN116159149B (zh) * 2023-02-27 2024-11-15 上海中医药大学 一种基于血小板的免疫连接器的制备方法及应用
CN118599772A (zh) * 2024-06-12 2024-09-06 深圳市第三人民医院(深圳市肝病研究所) 工程化免疫细胞、包含其的药物组合物及制备方法和应用
CN119662531A (zh) * 2024-12-19 2025-03-21 中山大学·深圳 一种工程化血小板及其制备方法与其在1型糖尿病中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504122A (ja) * 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
US20180055891A1 (en) * 2016-08-29 2018-03-01 Yong Zhao Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
WO2018053010A1 (en) * 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents
JP2018520688A (ja) * 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504122A (ja) * 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2018520688A (ja) * 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
US20180055891A1 (en) * 2016-08-29 2018-03-01 Yong Zhao Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
WO2018053010A1 (en) * 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2020077037A9 (en) 2020-06-11
CN113164523A (zh) 2021-07-23
EP3863650A1 (en) 2021-08-18
US20210353679A1 (en) 2021-11-18
EP3863650A4 (en) 2022-09-14
WO2020077037A1 (en) 2020-04-16
CA3115778A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
Baharlooi et al. Mesenchymal stem cell-derived exosomes: a promising therapeutic ace card to address autoimmune diseases
US10034917B2 (en) Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory T cell phenotype
US20210353679A1 (en) Pd-l1 presenting platelets reverse new-onset type 1 diabetes
US20190175649A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
JP2019534898A (ja) 中枢神経系の疾患および障害を処置するための組成物および方法
CN112135639B (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
CN113750244A (zh) 内载化疗药物外背免疫检查点抑制剂纳米凝胶的工程化血小板及其制备方法和应用
Li et al. Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma
RS64754B1 (sr) Fasl-izrađeni biomaterijali sa imunomodularnom funkcijom
Liu et al. Adoptive CD8+ T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma
EP3866815B1 (en) Transplant tolerance induction with carbodiimide treated tolerizing vaccine
KR102025417B1 (ko) 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물
WO2019028469A1 (en) FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
Gu et al. Bioengineered extracellular vesicles presenting PD-L1 and Gal-9 to ameliorate new-onset primary ovarian insufficiency (POI)
Liu et al. YTHDF1-targeting nanoassembly reverses tumoral immune evasion through epigenetics and cell cycle modulation
KR20230116844A (ko) 면역 체크포인트 분자로 기능화된 조작된 세포 및 이의용도
Hwang et al. Improved islet transplantation outcome by the co-delivery of siRNAs for iNOS and 17β-estradiol using an R3V6 peptide carrier
Wang et al. CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
Wang et al. Natural Killer Cell‐Mimicking Hypoxia‐Responsive Nanomedicines for Tumor‐Specific Suppression and Immune Regulation
AU2020289326B2 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
Wang et al. A novel plasma membrane-phillic graphene oxide nanocarrier for neuropeptide delivery to generate tolerogenic dendritic cells in GVHD Immunotherapy
WO2018106982A1 (en) Compositions and methods for enhancing beta cell maturation, health and function
WO2023183953A1 (en) Delivery of dissociated islets cells within microporous annealed particle scaffold to treat type 1 diabetes
TW201701886A (zh) 用於心臟再生的治療性基因混合製劑
EP3212222A2 (en) Compositions and methods for antigen-specific tolerance

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240115

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022